Endometrial Cancer: Evidence of a Long-Term “Tail” - Comparing PD-1 and PD-L1 Regimens

Across the RUBY, NRG GY018 and AtTEnd trials, a clear long term tail is beginning to emerge in survival curves, especially for patients with dMMR tumors. These patients often experience rapid and durable responses, with survival curves flattening after approximately one year, which supports the potential for long lasting benefit. This pattern reflects the strong and consistent activity of PD 1 based therapy.PD L1 regimens also show promise, although their durability appears somewhat less pronounced overall. AtTEnd still demonstrated encouraging long term outcomes in dMMR disease. Differences between PD 1 and PD L1 regimens may relate to variations in mechanisms, study populations or trial design. In clinical discussions, physicians emphasize that PD 1 based therapy currently offers the deepest and most consistent durability, while PD L1 based approaches remain valuable in specific clinical and molecular contexts.